Current status and future directions: Management of colon cancer with peritoneal dissemination

Future Oncology

Volumn 4, Issue 5, 2008, Pages 671-679

  Kerscher, Alexander ^a   Esquivel, Jesus ^a  

^a ST AGNES HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; MITOMYCIN C;

CANCER ADJUVANT THERAPY; CANCER CLASSIFICATION; CANCER INVASION; CANCER MORTALITY; CANCER STAGING; CANCER SURVIVAL; CARCINOMATOUS PERITONITIS; COLORECTAL CANCER; CYTOREDUCTIVE SURGERY; CYTOTOXICITY; HUMAN; HYPERTHERMIC THERAPY; MORBIDITY; PATHOPHYSIOLOGY; PATIENT SELECTION; POSTOPERATIVE CARE; PREOPERATIVE CARE; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; SCORING SYSTEM; SPLENECTOMY; SURGICAL APPROACH; SURGICAL TECHNIQUE; SYSTEMIC THERAPY; TREATMENT INDICATION;

ADENOCARCINOMA; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CLINICAL TRIALS AS TOPIC; COLONIC NEOPLASMS; COMBINED MODALITY THERAPY; DIGESTIVE SYSTEM SURGICAL PROCEDURES; HUMANS; PERITONEAL NEOPLASMS;

EID: 55249105214     PISSN: 14796694     EISSN: 17448301     Source Type: Journal    
DOI: 10.2217/14796694.4.5.671     Document Type: Review

References (35)

1. Hurwitz HI, Fehrenbacher L, Hainsworth JD et al.: Bevacizumab in combination with fluorouracil and leucovorin: an active regimen for first-line metastatic colorectal cancer. J. Clin. Oncol. 23(15), 3502-3508 (2005).
2. Sadeghi B, Arvieux C, Glehen O et al.: Peritoneal carcinomatosis from non-gynecologic malignancies: results of the EVOCAPE 1 multicentric prospective study. Cancer 88(2), 358-363 (2000).
3. Esquivel J, Sugarbaker PH: Clinical presentation of the pseudomyxorna peritonei syndrome. Br. J. Surg. 87(10), 1414-1418 (2000).
4. Zoetmulder FA: Cancer cell seeding during abdominal surgery: experimental studies. Cancer Treat. Res. 82, 155-161 (1996).
5. Look M, Chang D, Sugarbaker PH: Long-term results of cytoreductive surgery for advanced and recurrent epithelial ovarian cancers and papillary serous carcinoma of the peritoneum. Int. J. Gynecol. Cancer 14 (1), 35-41 (2004).
6. Sugarbaker PH, Cunliffe WJ, Belliveau J et al.: Rationale for integrating early postoperative intraperitoneal chemotherapy into the surgical treatment of gastrointestinal cancer. Semin. Oncol. 16(4 Suppl. 6), 83-97 (1989).
7. Sugarbaker PH: New standard of care for appendiceal epithelial neoplasms and pseudomyxoma peritonei syndrome? Lancet Oncol. 7(1), 69-76 (2006).
8. Esquivel J, Sugarbaker P: Management of Peritoneal Surface Malignancy: The Surgeon's Role. In: Current Surgical Therapy. Cameron JL (Ed). MOSBY, PA, USA 246-251 (2008).
9. Sugarbaker PH, Yan TD, Stuart OA, Yoo D: Comprehensive management of diffuse malignant peritoneal mesothelioma. Eur. J. Surg. Oncol. 32 (6), 686-691 (2006).
10. Katz MH, Barone RM: The rationale of perioperative intraperitoneal chemotherapy in the treatment of peritoneal surface malignancies. Surg. Oncol. Clin. N. Am. 12(3), 673-688 (2003).
11. Verwaal VJ, van Ruth S, de Bree E et al.: Randomized trial of cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy and palliative surgery in patients with peritoneal carcinomatosis of colorectal cancer. J. Clin. Oncol. 21(20), 3737-3743 (2003).
12. Sugarbaker PH: Peritonectomy procedures. Ann. Surg. 221(1), 29-42 (1995).
13. Yan TD, Haveric N, Carmignani CP, Bromley CM, Sugarbaker PH: Computed tomographic characterization of malignant peritoneal mesothelioma. Tumori 91(5), 394-400 (2005).
14. de Bree E, Koops W, Kroger R, van Ruth S, Verwaal VJ, Zoetmulder FA: Preoperative computed tomography and selection of patients with colorectal peritoneal carcinomatosis for cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Eur. J. Surg. Oncol. 32(1), 65-71 (2006).
15. Garofalo A, Valle M: Staging videolaparoscopy of peritoneal carcinomatosis. Tumori 89 (Suppl. 4), 70-77 (2003).
16. Pomel C, Appleyard TL, Gouy S, Rouzier R, Elias D: The role of laparoscopy to evaluate candidates for complete cytoreduction of peritoneal carcinomatosis and hyperthermic intraperitoneal chemotherapy. Eur. J. Surg. Oncol. 31(5), 540-543 (2005).
17. Jacquet P, Sugarbaker PH: Clinical research methodologies in diagnosis and staging of patients with peritoneal carcinomatosis. Cancer Treat. Res. 82, 359-374 (1996).
18. Elias D, Blot F, El Otmany A et al.: Curative treatment of peritoneal carcinomatosis arising from colorectal cancer by complete resection and intraperitoneal chemotherapy. Cancer 92(1), 71-76 (2001).
19. Tentes AA, Tripsiannis G, Markakidis SK et al. Peritoneal cancer index: a prognostic indicator of survival in advanced ovarian cancer. Eur. J. Surg. Oncol. 29 (1), 69-73 (2003).
20. Elias D, Sideris L, Pocard M et al. Efficacy of intraperitoneal chemohyperthermia with oxaliplatin in colorectal peritoneal carcinomatosis. Preliminary results in 24 patients. Ann. Oncol. 15 (5), 781-785 (2004).
21. Sugarbaker PH: Successful management of microscopic residual disease in large bowel cancer. Cancer Chemother. Pharmacol. 43(Suppl.), S15-S25 (1999).
22. Shen P, Hawksworth J, Lovato J et al.: Cytoreductive surgery and intraperitoneal hyperthermic chemotherapy with mitomycin C for peritoneal carcinomatosis from nonappendiceal colorectal carcinoma. Ann. Surg. Oncol. 11(2), 178-186 (2004).
23. Verwaal VJ, van Tinteren H, van Ruth S, Zoetmulder FA: Predicting the survival of patients with peritoneal carcinomatosis of colorectal origin treated by aggressive cytoreduction and hyperthermic intraperitoneal chemotherapy. Br. J. Surg. 91(6), 739-746 (2004).
24. Elias D, Delperro JR, Sideris L et al.: Treatment of peritoneal carcinomatosis from colorectal cancer: impact of complete cytoreductive surgery and difficulties in conducting randomized trials. Ann. Surg. Oncol. 11(5), 518-521 (2004).
25. Elias D, Raynard B, Farkhondeh F et al.: Peritoneal carcinomatosis of colorectal origin. Gastroenterol. Clin. Biol. 30(10), 1200-1204 (2006).
26. Glehen O, Kwiatkowski F, Sugarbaker PH et al.: Cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for the management of peritoneal carcinomatosis from colorectal cancer: a multi-institutional study. J. Clin. Oncol. 22(16), 3284-3292 (2004).
27. Verwaal VJ, Bruin S, Boot H, van Slooten G, van Tinteren H: 8-year follow-up of randomized trial: cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy in patients with peritoneal carcinomatosis of colorectal cancer. Ann. Surg. Oncol. 15(9), 2426-2432 (2008).
28. Yan TD, Black D, Savady R, Sugarbaker PH: Systematic review on the efficacy of cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for peritoneal carcinomatosis from colorectal carcinoma. J. Clin. Oncol. 24(24), 4011-4019 (2006).
29. Sugarbaker PH, Alderman R, Edwards G et al.: Prospective morbidity and mortality assessment of cytoreductive surgery plus perioperative intraperitoneal chemotherapy to treat peritoneal dissemination of appendiceal mucinous malignancy. Ann. Surg. Oncol. 13(5), 635-644 (2006).
30. McQuelton RP, Loggie BW, Fleming RA, Russell GB, Lehman AB, Rambo TD: Quality of life after intraperitoneal hyperthermic chemotherapy (IPHC) for peritoneal carcinomatosis, Eur. J. Surg. Oncol. 27(1), 65-73 (2001).
31. McQuellon RP, Loggie BW, Lehman AB et al.: Long-term survivorship and quality of life after cytoreductive surgery plus intraperitoneal hyperthermic chemotherapy for peritoneal carcinomatosis. Ann. Surg. Oncol. 10(2), 155-162 (2003).
32. Schmidt U, Dahlke MH, Klempnauer J, Schlitt HJ, Piso P: Perioperative morbidity and quality of life in long-term survivors following cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Eur. J. Surg. Oncol. 31(1), 53-58 (2005).
33. Tuttle TM, Zhang Y, Greeno E, Knutsen A: Toxicity and quality of life after cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy. Ann. Surg. Oncol. 13 (12), 1627-1632 (2006).
34. Shen J, Zhu Z: Catumaxomab, a rat/murine hybrid trifunctional bispecific monoclonal antibody for the treatment of cancer. Curr. Opin. Mol. Ther. 10(3), 273-284 (2008).
35. Burges A, Wimberger P, Kumper C et al.: Effective relief of malignant ascites in patients with advanced ovarian cancer by a trifunctional anti-EpCAM x anti-CD3 antibody: a Phase I/II study. Clin. Cancer Res. 13(13), 3899-3905 (2007).